Your browser doesn't support javascript.
loading
Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil
Tauil, Márcia de Cantuária; Carvalho, Cleidiane Santos Rodrigues de; Vieira, Ataiza César; Waldman, Eliseu Alves.
  • Tauil, Márcia de Cantuária; Universidade de São Paulo. Faculdade de Saúde Pública. São Paulo. BR
  • Carvalho, Cleidiane Santos Rodrigues de; Universidade de São Paulo. Faculdade de Saúde Pública. São Paulo. BR
  • Vieira, Ataiza César; Universidade de São Paulo. Faculdade de Saúde Pública. São Paulo. BR
  • Waldman, Eliseu Alves; Universidade de São Paulo. Faculdade de Saúde Pública. São Paulo. BR
Braz. j. infect. dis ; 18(4): 379-386, Jul-Aug/2014. tab, graf
Article in English | LILACS | ID: lil-719306
ABSTRACT

OBJECTIVES:

To analyze the behavior of meningococcal disease in the Federal District, Brazil, from 2005 to 2011, and to assess the direct impact of the meningococcal serogroup C conjugate vaccine.

METHODS:

A descriptive study of cases of meningococcal disease among residents of the Federal District. We included in the study confirmed cases of meningococcal disease reported to the local surveillance. To reduce underreporting we compared data to the Brazilian Mortality Database and the Public Health Laboratory Database. We studied sociodemographic, clinical, and pathogen-related variables. For the assessment of the impact of meningococcal serogroup C conjugate vaccine, which was introduced in 2010 for children under two years of age, we compared the incidence of meningococcal disease before and after vaccine introduction in the recommended age groups for vaccination.

RESULTS:

We identified 309 cases of meningococcal disease, of which 52.1% were males. The average case fatality rate was 20.7%, the median age was three years and there was a predominance of serogroup C (70.2%) and C23P1.14-6 phenotype throughout the study period. In 2005-2009, 2010 and 2011, the incidence rates of meningococcal disease were 2.0, 1.8 and 0.8/100,000 inhabitants/year, while mortality rates were 0.4, 0.4 and 0.2/100,000 inhabitants/year, respectively. In the first and last periods, the incidence in poorer and more affluent areas were, respectively, 2.0 and 0.8, and 0.9 and 0.0/100,000 inhabitants/year. Comparing 2009 (the year prior to the introduction of meningococcal serogroup C conjugate vaccine) and 2011, there was 85% reduction in the incidence of serogroup C meningococcal disease in children under four years of age, from 9.0 to 1.3/100,000 (p < 0.01).

CONCLUSIONS:

The meningococcal serogroup C conjugate vaccine strategy implemented in Brazil proved highly effective and had a strong direct impact on the target population. However, case ...
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Meningococcal Vaccines / Meningococcal Infections / Neisseria meningitidis Type of study: Evaluation studies / Incidence study / Prognostic study / Screening study Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Infant, Newborn Country/Region as subject: South America / Brazil Language: English Journal: Braz. j. infect. dis Journal subject: Communicable Diseases Year: 2014 Type: Article / Project document Affiliation country: Brazil Institution/Affiliation country: Universidade de São Paulo/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Meningococcal Vaccines / Meningococcal Infections / Neisseria meningitidis Type of study: Evaluation studies / Incidence study / Prognostic study / Screening study Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Infant, Newborn Country/Region as subject: South America / Brazil Language: English Journal: Braz. j. infect. dis Journal subject: Communicable Diseases Year: 2014 Type: Article / Project document Affiliation country: Brazil Institution/Affiliation country: Universidade de São Paulo/BR